Floatz logo

AZD 8186

Squamous Non-Small Cell Lung Cancer sqNSCLC

AstraZenecaSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

47 Active assets in the Squamous Non-Small Cell Lung Cancer sqNSCLC cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Qilu Hospital of Shandong University
Phase 4BBB
Carboplatin
zhang yi
Phase 3BBB
Docetaxel
Shanghai JMT-Bio Inc.
Phase 3BBB
Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Phase 3BB
ETOPOSIDE
Barbara Ann Karmanos Cancer Institute
Phase 3BB

View all 50 →

Same molecule, other indications

AZD 8186 is also rated in:

triple-negative breast carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
castration-resistant prostate carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →